http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110548029-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75df1d17c60d932d89d802d7031b7bfa |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
| filingDate | 2019-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0859916cf11a6671a0bed62b86c1e213 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_744044cb98187705ed9d05e1a76a38d5 |
| publicationDate | 2019-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110548029-A |
| titleOfInvention | Application of osimertinib mesylate in the preparation of medicaments for the treatment of fungal infections |
| abstract | The invention belongs to the field of medicine preparation, and particularly relates to the application of osimertinib mesylate in the preparation of a medicine for treating fungal infections. Osimertinib mesylate has a therapeutic effect on fungal infections, especially when used in combination with fluconazole, it not only has a good bacteriostatic effect but also has a bactericidal effect against fungal infections, and also has a broad-spectrum antibacterial effect. Clinically, fluconazole has good killing effect on Candida albicans resistant strains, Cryptococcus neoformans and Saccharomyces cerevisiae. The present invention verifies that the bactericidal mechanism of osimertinib mesylate is related to the destruction of pH homeostasis in cell vesicles through experiments. Therefore, the present invention provides new evidence and ideas for developing pH homeostasis as an antifungal infection drug from the perspective of large-scale screening to mechanism verification. The invention finds that the genes PDR5 and VMA1 are the drug targets of osimertinib mesylate against fungal infection, and provides a new development direction and action mechanism for the treatment of fungal infection and the research and development of therapeutic drugs. |
| priorityDate | 2019-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.